Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Data up to Jan 2025
Total Citations Per Year
Abstract
References (11)
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 • 5,189 citations
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 • 2,749 citations
Chronic Myeloid Leukemia
1999 • 1,639 citations
The Biology of Chronic Myeloid Leukemia
1999 • 1,308 citations
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
2000 • 789 citations
The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells
1997 • 646 citations
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
2000 • 511 citations
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines
2000 • 420 citations
Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
2000 • 332 citations
3 Signal transduction pathways involved in BCR-ABL transformation
1997 • 74 citations
STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation
2000 • 2 citations